Mazie Tsang, M.D.

Closed for Enrollment

• An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL) (PROSPECT Study) Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. 

• Longitudinal quality of life for older adults with indolent lymphomas (QOL-LEO) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to identify factors important to decision-making for older adults with indolent lymphomas and to identify minimum clinically significant differences in QOL domains are important to older patients in their decision-making about clinical management.  And to characterize longitudinal health-related quality of life (QOL) for older adults with indolent lymphomas.